Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Genta Inc. (GETA.OB) – An Innovator in Cancer Treatment Drugs

|Includes: Genta (GETA)

Genta Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of people with cancer. The company has built a broad portfolio of proprietary products in various stages of clinical development. Genta’s drugs in development include Ganite (gallium nitrate), Genasense (oblimersen sodium), Tesetaxel, and oral gallium.

Here is a brief overview of Genta’s four cancer drugs:

• Tesetaxel is a novel, orally-absorbed taxane that is in the same class of drugs as docetaxel and paclitaxel. Tesetaxel has completed several Phase 2 clinical trials. The company has initiated studies of the drug in patients with solid tumors, particularly stomach cancers.
• Genasense injection is a modified DNA-based antisense drug that may enhance the effectiveness of anti-cancer therapy. Enrollment of patients with advanced melanoma in a Phase 3 study is complete.
• Ganite is being currently being marketed by Genta in the United States. It is used for treatment of patients with cancer-related hypercalcemia that is resistant to hydration.
• Oral gallium is in Phase 1 studies for treatment of patients with various conditions associated with bone loss.

For further information on Genta and its drugs in development, please visit its website at genta.com.

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net


Disclosure: no positions